The second act is the strategy: this season's best franchises show their next move
Harmony, TG, Madrigal and BioMarin all paired strong quarters with dated plans to widen what their lead medicines can do. Investors should expect that pairing from every franchise.
Strong quarters are no longer enough
Madrigal's Rezdiffra posted $431.3 million in third-quarter net sales, up 50% year over year, and the company's first quarter of profitability. Harmony's WAKIX brought in $269 million and the company reiterated full-year guidance of $1.0 billion to $1.04 billion. TG Therapeutics raised full-year revenue guidance to approximately $1 billion, with about $233 million of BRIUMVI U.S. net product revenue in the quarter. These are excellent numbers.
What stands out is that none of these companies stopped at the number. Each attached a second act to it, with specifics and dates. My position is that this is now the standard, and companies that report a strong quarter without one are leaving the most important half of the story untold.
What the second acts look like
Harmony pairs WAKIX with a pitolisant GR application under FDA review (PDUFA date April 1, 2027), a pitolisant HD Phase 3 readout in 2027 with a target PDUFA date in 2028, and an orexin agonist, BP-205, with multiple-ascending dose data in hand. It says its multi-layered IP strategy across active legal proceedings supports confidence in WAKIX exclusivity to March 2030. It also announced a CEO succession effective January 1, 2027.
TG's version is about convenience and reach. It presented seven-year BRIUMVI follow-up data and positive ENHANCE results supporting single-infusion initiation, and reported progress toward a quarterly self-administered subcutaneous treatment. Madrigal started a new outcomes trial, MAESTRO-CSPH, in well-compensated MASH cirrhosis (F4c), while MAESTRO-NASH OUTCOMES data are expected in late 2027. BioMarin has a May 30, 2027 PDUFA date for VOXZOGO in hypochondroplasia and has added a new investigational Fabry asset.
Together, these show growth being engineered ahead of time. The lead product's next formulation, dosing regimen, patient population or successor is mapped out in public while the current product is still accelerating.
The strongest counter-argument
The fair objection is that a roadmap is not revenue. Formulation and dosing updates can be incremental, and trial readouts can disappoint. Legal proceedings are, by definition, unresolved: a company can express confidence in exclusivity to March 2030, but a confident press-release line is not a court outcome. The more a growth story leans on timelines that have not yet been met, the more it depends on execution that the quarter's results cannot verify. Skeptics will also say that a second act can serve as a distraction from the first.
That is right, and it is why the dates matter. A stated PDUFA date or data window can be checked. This season's disclosures are testable in a way that vague talk of a pipeline is not. A company that says April 1, 2027 or late 2027 has agreed to be measured.
Why this matters now
Mature franchises in this group are also getting more expensive to defend. ANI reported 27.6% revenue growth, with Purified Cortrophin Gel up 36.1%, and chose to announce an offer for Egetis Therapeutics to add scale in rare disease. BioMarin credited a more diversified portfolio after acquiring Amicus for part of its 32% growth, and it guided with caution because of order timing uncertainty and two acquired IPR&D charges. Whether built internally or bought, the logic is the same: the current engine is strong, and it is being reinforced before it needs to be.
The industry that earns the most from a product while it is growing is the industry with the most reason to plan its next move early.
What leaders should do
- Pair every strong-quarter headline with a dated second act, such as a regulatory date, readout window or new-population trial, so that investors can hold you to it.
- Fund the next version of the lead asset while it is still accelerating, whether through formulation, dosing, indication or a successor, rather than waiting for pressure on the original.
- Be candid about what is unresolved, including legal proceedings, order timing and acquired-asset charges, and separate it from the operating story.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
The second act is where this quarter's money was made
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
A fee schedule rate is not a durable price: coverage is the real asset
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Plan the exit before the readout: strategic alternatives shouldn't start after a miss
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.